| Description | MK-0493 is an effective and selective agonist of the melanocortin receptor 4 (MC4R). It also demonstrated significant reductions in energy intake. |
| In vivo | MK-0493 is shown to promote robust weight loss activity following oral administration in preclinical animal models. That suggesting the drug can access the target site in the hypothalamus. MK-0493 dose-dependently enhances electrically evoked increases in ICP [2][3]. |
| molecular weight | 546.09 |
| Molecular formula | C30H38ClF2N3O2 |
| CAS | 455956-93-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Krishna R, etal. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009 Dec;86(6):659-66. 2. Sezen SF, et al. Intracavernosal pressure monitoring in mice: responses to electrical stimulation of the cavernous nerve and to intracavernosal drug administration. J Androl. 2000 Mar-Apr;21(2):311-5. 3. Hong Q, et al. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2330-4. |